HC Wainwright cut shares of Aptinyx (NASDAQ:APTX – Get Rating) from a buy rating to a neutral rating in a research note published on Tuesday, The Fly reports. HC Wainwright also issued estimates for Aptinyx's Q1 2023 earnings at ($0.15) EPS, Q2 2023 earnings at ($0.10) EPS, Q3 2023 earnings at ($0.06) EPS, Q4 2023 earnings at ($0.04) EPS and FY2023 earnings at ($0.36) EPS.

Several other equities analysts have also issued reports on the stock. SVB Securities lowered shares of Aptinyx from an outperform rating to a market perform rating in a report on Wednesday, March 1st. SVB Leerink reaffirmed a market perform rating and set a $0.50 target price on shares of Aptinyx in a research note on Wednesday, March 1st. Eight equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Aptinyx has a consensus rating of Hold and an average price target of $2.58.

Aptinyx Stock Down 4.0 %

Aptinyx stock opened at $0.15 on Tuesday. The firm has a 50 day moving average price of $0.44 and a two-hundred day moving average price of $0.37. The company has a debt-to-equity ratio of 0.51, a quick ratio of 27.45 and a current ratio of 27.45. Aptinyx has a 52-week low of $0.14 and a 52-week high of $3.17. The firm has a market cap of $10.14 million, a price-to-earnings ratio of -0.14 and a beta of 1.39.

Institutional Trading of Aptinyx

Hedge funds have recently bought and sold shares of the business. Millennium Management LLC lifted its stake in shares of Aptinyx by 10.8% in the fourth quarter. Millennium Management LLC now owns 1,333,622 shares of the company's stock valued at $391,000 after buying an additional 129,635 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Aptinyx by 14.3% in the fourth quarter. Renaissance Technologies LLC now owns 618,226 shares of the company's stock valued at $176,000 after purchasing an additional 77,200 shares in the last quarter. HBK Sorce Advisory LLC grew its holdings in Aptinyx by 100.0% during the fourth quarter. HBK Sorce Advisory LLC now owns 52,000 shares of the company's stock worth $53,000 after buying an additional 26,000 shares in the last quarter. Jane Street Group LLC raised its position in Aptinyx by 213.3% in the 3rd quarter. Jane Street Group LLC now owns 105,771 shares of the company's stock valued at $39,000 after buying an additional 72,006 shares during the last quarter. Finally, RA Capital Management L.P. bought a new position in Aptinyx during the 3rd quarter valued at $720,000. Institutional investors and hedge funds own 45.93% of the company's stock.

About Aptinyx

(Get Rating)

Aptinyx Inc is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G.

Recommended Stories

• Get a free copy of the StockNews.com research report on Aptinyx (APTX)
• Fossil Group: Should You Bet On Consumer Discretionary In 2023?
• BJ's Wholesale Club Stock Moves Higher After Strong Results
• Monthly Realty Income is About to Get Bigger
• 3 Large Cap Dividend Challengers for Millennial Investors
• Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.